Aminologics Co.,Ltd.
Financials
Valuation Metrics
Aminologics Co.,Ltd.'s Market Cap is ₩905B. At end of 2025 it was ₩1052B. Ranked #1297 of 2,436 in KR market (top 53%), #706 of 1,649 on KOSDAQ (top 43%), #150 of 294 in Materials (top 51%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 90.52B KRW | KR#1,297/2,436 Sec#150/294 |
| Revenue | 22.68B KRW | KR#2,110/2,436 Sec#281/294 |
| Net Income | 2.26B KRW | KR#1,330/2,436 Sec#164/294 |
| Total Assets | 87.63B KRW | KR#1,845/2,436 Sec#254/294 |
| Net Assets | 57.11B KRW | KR#1,784/2,436 Sec#240/294 |
| Employees | 38 | KR#2,125/2,436 Sec#263/294 |
| Value | ||
| P/E | 40.07x | KR#1,320/2,436 Sec#173/294 |
| P/B | 1.58x | KR#1,822/2,436 Sec#256/294 |
| P/S | 3.99x | KR#2,087/2,436 Sec#278/294 |
| EV/EBITDA | 20.20x | KR#1,018/2,436 Sec#130/294 |
| Profitability | ||
| ROE | 3.96% | KR#1,121/2,436 Sec#109/294 |
| ROA | 2.58% | KR#1,024/2,436 Sec#107/294 |
| Op. Margin | 16.37% | KR#233/2,436 Sec#12/294 |
| Revenue Growth | 13.87% | KR#788/2,436 Sec#78/294 |
| Earnings Growth | -54.19% | KR#1,225/2,436 Sec#160/294 |
| Financial Health | ||
| Debt Ratio | 153.43% | KR#1,235/2,436 Sec#158/294 |
| Total Debt | 15.93B KRW | KR#1,449/2,436 Sec#217/294 |
| Cash | 31.48B KRW | KR#978/2,436 Sec#121/294 |
| Current Ratio | 2.75x | KR#677/2,436 Sec#70/294 |
| Net Debt/EBITDA | -4.19x | KR#154/2,436 Sec#16/294 |
| Performance | ||
| 1Y Return | -5.78% | KR#847/2,436 Sec#89/294 |
| 1M Return | -4.82% | KR#1,379/2,436 Sec#174/294 |
| From 52W High | -47.06% | KR#1,058/2,436 Sec#144/294 |
| 1Y MDD | -47.39% | KR#810/2,436 Sec#114/294 |
| Trading | ||
| Volume | 72,909 shares | KR#1,122/2,436 Sec#108/294 |
| Foreign Own. | 2.49% | KR#1,041/2,436 Sec#110/294 |
| Per Share | ||
| EPS | 26 KRW | KR#1,484/2,436 Sec#187/294 |
| BPS | 650 KRW | KR#2,368/2,436 Sec#291/294 |
Company Info
Aminologics, established in 1997 and KOSDAQ listed in 2004, is a small and medium-sized venture enterprise. The company acquired the active pharmaceutical ingredient (API) business rights from Sam-O Pharmaceutical in 2015, supplying APIs for stroke, eye diseases, and dermatitis to domestic pharmaceutical companies. Since 2009, Aminologics has been developing various products, including D-Serine, through its amino acid derivative business. Recognized for its quality by global customers, the company is actively engaged in research and development to capture the peptide new drug market, receiving new development requests. Aminologics is headquartered in Gangnam-gu, Seoul.